细胞因子诱导的杀伤细胞的研究进展

被引：3

作者：

袁玉涛

机构：

[1] 黑龙江省肿瘤研究所

来源：

国际免疫学杂志 | 2007年 / 03期

关键词：

细胞因子诱导的杀伤细胞; 细胞毒活性; 临床应用;

D O I：

暂无

中图分类号：

R730 [一般性问题];

学科分类号：

摘要：

正常人或患者外周血、骨髓单个核细胞中定期加入IFN-γ、IL-1、IL-2、CD3mAb经2-4W的诱导可获得大量的新型肿瘤杀伤细胞—细胞因子诱导的杀伤细胞CIK,此细胞增殖旺盛杀伤活性高。CIK在体内和体外都具有非MHC限制抗肿瘤活性,在临床上已经用于治疗多种恶性肿瘤表现出强大的杀瘤活性,是一种很好的免疫治疗方法。

引用

收藏

页码：163 / 166

相关论文

共 11 条

[1] 树突细胞联合细胞因子诱导的杀伤细胞对耐药K562细胞的体外杀伤作用 [J].

陈宝安 ;

李曼 ;

孙载阳 ;

李翠萍 ;

高冲 ;

孙耘玉 ;

王骏 ;

傅强 ;

陈津 .

中华血液学杂志, 2005, (06) :355-358

[2]

Cytokine-induced killer cells showing multidrug resistance and remaining cytotoxic activity to tumor cells after transfected with mdr1 cDNA[J]. 李惠芳,杨永红,石永进,王逸群,朱平.Chinese Medical Journal. 2004(09)

[3] ANTITUMOR IMMUNITY AND VACCINE EFFECT INDUCED BY IL-12 SYNERGIZES B7-1 GENE TRANSFECTED CELLS [J].

王志华 ;

李弘 ;

张春艳 .

Chinese Journal of Cancer Research, 2003, (01) :8-11

[4] 细胞因子诱导的杀伤细胞降低乳腺癌耐药细胞系对阿霉素的耐受效应 [J].

石永进 ;

虞积仁 ;

朱平 ;

马明信 ;

岑溪南 ;

董玉君 ;

袁家颖 .

北京大学学报(医学版), 2001, (05) :415-418

[5] Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy [J].

Marin, Virna ;

Dander, Erica ;

Biagi, Ettore ;

Introna, Martino ;

Fazio, Grazia ;

Biondi, Andrea ;

D'Amico, Giovanna .

EXPERIMENTAL HEMATOLOGY, 2006, 34 (09) :1219-1229

[6] The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab [J].

Kornacker, M ;

Verneris, MR ;

Kornacker, B ;

Ganten, TM ;

Scheffold, C ;

Negrin, RS .

CYTOTHERAPY, 2006, 8 (01) :13-23

[7] Enhanced antitumor immunity by murine cytokine activated T lymphocytes after cocultured with bone marrow derived dendritic cells pulsed with whole tumor lysates [J].

Zhang, S ;

Wang, Q ;

Li, WF ;

Wang, HY ;

Zhang, HJ .

LEUKEMIA RESEARCH, 2004, 28 (10) :1085-1088

[8] A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon α and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells [J].

Flieger, D ;

Kufer, P ;

Beier, I ;

Sauerbruch, T ;

Schmidt-Wolf, IGH .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 49 (08) :441-448

[9] Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis [J].

Verneris, MR ;

Kornacker, M ;

Mailänder, V ;

Negrin, RS .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 49 (06) :335-345

[10] Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules [J].

Liu, J ;

Finke, J ;

Krauss, JC ;

Shu, SY ;

Plautz, GE .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 46 (05) :268-276